Xeris Biopharma Holdings (XERS) Change in Acquisitions & Divestments (2020 - 2024)

Xeris Biopharma Holdings has reported Change in Acquisitions & Divestments for 5 years, with the latest figure at $10.2 million in Q4 2024.

• For the quarter ending Q4 2024, Change in Acquisitions & Divestments fell 31.76% year-over-year to $10.2 million; the trailing twelve-month figure through Sep 2025 stood at $10.2 million (down 77.25% YoY), and the FY2024 full-year result was $40.2 million, up 0.59% from the prior year.
• Change in Acquisitions & Divestments for Q4 2024 stood at $10.2 million, down from $15.0 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $34.6 million in Q1 2021, with the low at $5.0 million in Q1 2024.
• Historically, Change in Acquisitions & Divestments has averaged $14.8 million across 5 years, with a median of $11.3 million in 2021.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments tumbled 80.66% — and 2023, when it jumped 117.86%.
• Xeris Biopharma Holdings' Change in Acquisitions & Divestments stood at $17.8 million in 2020, then plunged by 41.14% to $10.5 million in 2021, then fell by 11.43% to $9.3 million in 2022, then soared by 61.29% to $15.0 million in 2023, then plunged by 31.76% to $10.2 million in 2024.
• The last three Change in Acquisitions & Divestments figures came in at $10.2 million (Q4 2024), $15.0 million (Q3 2024), and $10.0 million (Q2 2024), per Business Quant data.